2-(5-ethoxy-1H-indol-3-yl)ethan-1-amine hydrochloride | 65-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(5-ethoxy-1H-indol-3-yl)ethan-1-amine hydrochloride
• 英文别名: 2-(5-ethoxy-indol-3-yl)-ethylamine; hydrochloride；2-(5-Aethoxy-indol-3-yl)-aethylamin; Hydrochlorid；2-(5-ethoxy-1H-indol-3-yl)ethanamine;hydrochloride
• CAS: 65-37-2
• 化学式: C₁₂H₁₆N₂O*ClH
• 分子量: 240.733
• InChiKey: HTPGNGGIKUWUBE-UHFFFAOYSA-N

物化性质

• 熔点：
  247-249 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.49
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-chloropyrimidin-4-yl)-1-methyl-indazol-4-amine 、 2-(5-ethoxy-1H-indol-3-yl)ethan-1-amine hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 乙二醇 为溶剂， 生成 N²-[2-(5-ethoxy-1H-indol-3-yl)ethyl]-N⁴-(1-methylindazol-4-yl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer

  摘要：

  该发明提供了一种新颖的式I的吲唑取代二氨基嘧啶化合物，以及制备这种化合物的方法，包含这种化合物的药物组合物，以及利用这种化合物治疗包括癌症在内的疾病的方法；其中R1-R8如规范中定义。

  公开号：

  EP2711365A1

文献信息

• 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
  申请人：Chemilia AB

  公开号：EP2711364A1

  公开（公告）日：2014-03-26

  The invention provides novel indole- and benzimidazole-substituted diaminopyrimidines of formula I, to methods of preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for using such compounds in treatment of diseases including cancer; wherein R1-R3 are as defined in the specification.

  该发明提供了新型的公式I的吲哚和苯并咪唑取代的二氨基嘧啶化合物，以及制备这些化合物的方法，含有这些化合物的药物组合物，以及使用这些化合物治疗包括癌症在内的疾病的方法；其中R1-R3如规范中所定义。
• [EN] 4-(INDOLYL OR BENZIMIDAZOLYL)AMINO-2-(2-(INDOL-3-YL)ETHYL)AMINOPYRIMIDINES USEFUL FOR THE TREATMENT OF CANCER<br/>[FR] 4- (INDOLYLE OU BENZIMIDAZOLYLE) AMINO -2- (2- (INDOL -3-YL) ÉTHYL) AMINOPYRIMIDINES UTILES POUR LE TRAITEMENT DU CANCER
  申请人：CHEMILIA AB

  公开号：WO2014044755A1

  公开（公告）日：2014-03-27

  The invention provides novel indole- and benzimidazole-substituted diaminopyrimidines of formula I, to methods of preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for using such compounds in treatment of diseases including cancer; wherein R1-R3 are as defined in the specification.

  该发明提供了式I的新型吲哚和苯并咪唑取代的二氨基嘧啶化合物，以及制备这类化合物的方法，含有这类化合物的药物组合物，以及使用这类化合物治疗包括癌症在内的疾病的方法；其中R1-R3如规范中所定义。
• [EN] FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY<br/>[FR] DIAMIDES IMIDODICARBONIMIDIQUES LIÉS À UN ALKYLÈNE BICYCLIQUE FUSIONNÉ, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS DANS UNE THÉRAPIE
  申请人：NOVATARG INC

  公开号：WO2018106907A1

  公开（公告）日：2018-06-14

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5' adenosine monophosphate-activated protein kinase (AMPK).

  本发明提供了新型的融合的双环烷基亚乙基连接的咪唑二氨基碳亚胺二酰胺。具体来说，本文描述了N-[2-(吲哚-3-基)烷基]-连接的咪唑二氨基碳亚胺二酰胺和N-[2-(吡咯吡啶-3-基)烷基]-连接的咪唑二氨基碳亚胺二酰胺（化合物的结构式（I）或结构式（II）），以及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物，可用于治疗由于5'腺苷单磷酸活化蛋白激酶（AMPK）活性降低而引起的疾病和症状。
• Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
  申请人：NovaTarg, Inc.

  公开号：US11261157B2

  公开（公告）日：2022-03-01

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).

  本发明提供了新颖的融合双环烯基连接的咪唑二碳酰亚胺二酰胺。特别是，本发明描述了 N-[2-(吲哚-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺和 N-[2-(吡咯并吡啶-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺（式 (I) 或式 (II) 的化合物）及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物，可用于治疗由 5′单磷酸腺苷激活蛋白激酶（AMPK）活性降低引起的疾病和病症。
• FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY
  申请人：NovaTarg, Inc.

  公开号：US20190345103A1

  公开（公告）日：2019-11-14

  The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).